Carmine Therapeutics develops non-viral gene therapies using red blood cell extracellular vesicles (RBCEVs) to enhance nucleic acid delivery while minimizing immunogenicity and manufacturing challenges. Their REGENT® platform aims to provide effective treatments for a wide range of diseases by utilizing biocompatible and readily available RBCEVs.
Funding
$31.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HCFounders
Product
Problem
Current viral-based gene therapies face limitations including immunogenicity, restricted transgene capacity, and manufacturing complexities, hindering their broad application. Effective delivery of nucleic acids to target cells remains a significant challenge in gene therapy.
Solution
Carmine Therapeutics is developing non-viral gene therapies utilizing red blood cell extracellular vesicles (RBCEVs) to overcome the limitations of viral vectors. The REGENT® platform leverages the biocompatibility, availability, and modularity of RBCEVs to deliver nucleic acids effectively while minimizing immunogenicity. RBCEVs, naturally produced by red blood cells and lacking genetic material, can be obtained in large quantities and easily modified for nucleic acid loading and surface targeting. This approach enables the development of next-generation, disease-modifying gene therapies for a wide range of diseases. The platform aims to make genetic medicines more accessible by addressing the challenges associated with traditional viral-based methods.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing gene therapies for a broad spectrum of diseases, particularly those seeking to overcome the limitations of viral vectors.
Features
- Utilizes red blood cell extracellular vesicles (RBCEVs) as a non-viral delivery system
- RBCEVs are biocompatible and non-immunogenic, reducing adverse immune responses
- RBCEVs can be obtained in large quantities from a single unit of blood
- The REGENT® platform allows for manipulation of RBCEVs, including nucleic acid loading and surface modification
- Aims to overcome limitations of viral-based gene therapies, such as transgene capacity restrictions